Lifecore Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CHASKA, Minn., Jan. 16, 2026 (GLOBE NEWSWIRE) — Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”) a fully integrated contract development and manufacturing organization (“CDMO”), today announced that on January 14, 2026, the Lifecore compensation committee approved grants under Lifecore’s Equity Inducement Plan, as amended (the “Inducement Plan”) of restricted stock unit (“RSU”) awards with respect to an aggregate 1,738 shares of its common stock and stock options for an aggregate 8,775 shares of common stock to two newly hired employees of Lifecore. The RSU award and stock options were granted on January 14, 2026, pursuant to the offer letters between Lifecore and each employee, and as a material inducement to each employee joining Lifecore.

The RSU awards and stock options were approved by Lifecore’s compensation committee and were granted as inducement equity awards in accordance with Nasdaq Listing Rule 5635(c)(4) under the Inducement Plan.

The RSUs will vest and be settled on the third anniversary of the grant date, subject to continued employment. The stock options have an exercise price equal to Fair Market Value (as defined in the Inducement Plan) on the grant date and will vest as to one-third of the shares on the first anniversary of the grant date and as to 1/36th of the shares on each monthly grant date thereafter, subject to continued employment. The stock options have a seven-year term. The RSU award and stock options are each governed by an award agreement and the Inducement Plan.

About Lifecore Biomedical

Lifecore Biomedical, Inc. (Nasdaq: LFCR) is a fully integrated contract development and manufacturing organization (CDMO) that offers highly differentiated capabilities in the development, fill and finish of sterile injectable pharmaceutical products in syringes, vials, and cartridges, including complex formulations. As a leading manufacturer of premium, injectable-grade hyaluronic acid, Lifecore brings more than 40 years of expertise as a partner for global and emerging biopharmaceutical and biotechnology companies across multiple therapeutic categories to bring their innovations to market. For more information about the company, visit Lifecore’s website at www.lifecore.com.



Lifecore Biomedical, Inc. Contact Information:
Stephanie Diaz (Investors)
Vida Strategic Partners
415-675-7401
[email protected]

Tim Brons (Media)
Vida Strategic Partners
415-675-7402
[email protected]

Ryan D. Lake (CFO)
Lifecore Biomedical
952-368-6244
[email protected]

Source Capital Provides Update on Discount Management Program and Private Credit Investments and Announces Q4 Webcast

Source Capital Provides Update on Discount Management Program and Private Credit Investments and Announces Q4 Webcast

LOS ANGELES–(BUSINESS WIRE)–
The Board of Trustees of Source Capital (NYSE: SOR) (the “Fund”), today announced that for the Fund’s Discount Management Program (the “Program”) measurement period from January 1, 2025 through December 31, 2025, the Fund traded at an average discount to net asset value (NAV) of less than 10%. In fact, the Fund traded at a premium during the fourth quarter, peaking at a premium to NAV of 1.20% on November 28, 2025. As a result of the average discount to NAV remaining under 10%, the tender offer for calendar year 2025 under the Fund’s Program will not occur.

In addition to the contingent tender offer in place for calendar year 2026 (as described in the January 16, 2025 press release), the Board of Trustees (“Board”) approved a contingent tender offer for calendar year 2027. Under the terms of the updated Program, the Board approved extending the Program through the year ending December 31, 2027. Under the Program’s extension, the Fund will conduct a tender offer for 10% of the Fund’s outstanding shares of common stock at a price equal to 98% of NAV per share if its shares trade at an average discount to NAV of more than 10% during the measurement period from January 1, 2027 through December 31, 2027. Should a tender offer be required it shall close no later than June 30, 2028. In the future, the Board may determine to extend the Program beyond 2027.

The Fund’s portfolio managers, officers and Board do not intend to tender their shares if a tender is required under the Program for 2026.

In addition to the Program, the Fund will continue to implement its Stock Repurchase Program to repurchase stock at prices that are accretive to shareholders.

For the past few years, the Fund has been increasing its allocation to private credit investments and continues to make progress in this area. As of December 31, 2025, approximately 21.7% of NAV was invested in private credit and the combined invested plus committed capital to private credit was approximately 25.9% of NAV.

Finally, the Fund will host an investor call on February 26, 2026, at 1pm PST. Details of the call and how to submit questions will be posted at fpa.com.

About Source Capital

Source Capital is a closed-end investment company managed by First Pacific Advisors, LP. Its shares are listed on the New York Stock Exchange under the symbol “SOR.” The investment objective of the Fund is to seek maximum total return for shareholders from both capital appreciation and investment income to the extent consistent with protection of invested capital. The Fund may invest in longer duration assets like dividend paying equities and illiquid assets like private loans in pursuit of its investment objective and is thus intended only for those investors with a long-term investment horizon (greater than or equal to ~5 years).

You can obtain additional information by visiting the website at fpa.com, by email at [email protected], toll free by calling 1-800-982-4372, or by contacting the Fund in writing.

Important Disclosures

You should consider the Fund’s investment objectives, risks, and charges and expenses carefully before you invest.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy any securities nor shall there be any sale of the securities in any state in which such offer, solicitation or sale would be unlawful under the securities laws of any such state. In the event of a tender offer, there may be tax consequences for a stockholder. For example, a stockholder may owe capital gains taxes on any increase in the value of the shares over your original cost.

As with any stock, the price of the Fund’s common shares will fluctuate with market conditions and other factors. Shares of closed-end management investment companies frequently trade at a price that is less than (a “discount”) or more than (a “premium”) their net asset value. If the Fund’s shares trade at a premium to net asset value, there is no assurance that any such premium will be sustained for any period of time and will not decrease, or that the shares will not trade at a discount to net asset value thereafter. The Fund’s portfolio statistics and performance are available by visiting the website at https://fpa.com/fund/source-capital, by email at [email protected], toll free by calling 1-800-279-1241, or by contacting the Fund in writing.

Investments, including investments in closed-end funds, carry risks and investors may lose principal value. Capital markets are volatile and can decline significantly in response to adverse issuer, political, regulatory, market, or economic developments. It is important to remember that there are risks inherent in any investment and there is no assurance that any investment or asset class will provide positive performance over time. Value style investing presents the risk that the holdings or securities may never reach our estimate of intrinsic value because the market fails to recognize what the portfolio management team considers the true business value or because the portfolio management team has misjudged those values. In addition, value style investing may fall out of favor and underperform growth or other style investing during given periods. Non-U.S. investing presents additional risks, such as the potential for adverse political, currency, economic, social or regulatory developments in a country, including lack of liquidity, excessive taxation, and differing legal and accounting standards. Non-U.S. securities, including American Depository Receipts (ADRs) and other depository receipts, are also subject to interest rate and currency exchange rate risks.

Fixed income instruments are subject to interest rate, inflation and credit risks. Such investments may be secured, partially secured or unsecured and may be unrated, and whether or not rated, may have speculative characteristics. The market price of the Fund’s fixed income investments will change in response to changes in interest rates and other factors. Generally, when interest rates rise, the values of fixed income instruments fall, and vice versa. Certain fixed income instruments are subject to prepayment risk and/or default risk.

Private placements, including private credit and loans, are instruments that are not registered under the federal securities laws, and are generally eligible for sale only to certain eligible investors. Private placements may be illiquid, and thus more difficult to sell, because there may be relatively few potential purchasers for such investments, and in certain cases, the sale of such investments may also be restricted under securities laws.

The Fund may use leverage. While the use of leverage may help increase the distribution and return potential of the Fund, it also increases the volatility of the Fund’s net asset value (NAV), and potentially increases volatility of its distributions and market price. There are costs associated with the use of leverage, including ongoing dividend and/or interest expenses. There also may be expenses for issuing or administering leverage. Leverage changes the Fund’s capital structure through the issuance of preferred shares and/or debt, both of which are senior to the common shares in priority of claims. If short-term interest rates rise, the cost of leverage will increase and likely will reduce returns earned by the Fund’s common stockholders.

This material has been distributed for informational purposes only and should not be considered as investment advice or a recommendation of any particular security, strategy or investment product. No part of this material may be reproduced in any form, or referred to in any other publication, without express written permission.

Investor:

Ryan Leggio, Partner

[email protected]

310-996-5484

Media:

Tucker Hewes, Hewes Communications, Inc., 212-207-9451, [email protected]

KEYWORDS: California United States North America

INDUSTRY KEYWORDS: Banking Professional Services Finance

MEDIA:

Logo
Logo

Defiance ETFs Announces Closure of Select Funds

NEW YORK, Jan. 16, 2026 (GLOBE NEWSWIRE) — Tidal Financial Group and Defiance ETFs today announced their decision to close and liquidate eight exchange-traded funds listed on the Nasdaq:

Defiance Leveraged Long + Income PLTR ETF (Nasdaq: PLT)
Defiance Leveraged Long + Income SMCI ETF (Nasdaq: SMCC)
Defiance Leveraged Long + Income HOOD ETF (Nasdaq: HOOI)
Defiance Leveraged Long + Income Ethereum ETF (Nasdaq: ETHI)
Defiance Leveraged Long + Income AMD ETF (Nasdaq: AMDU)
Defiance Leveraged Long + Income HIMS ETF (Nasdaq: HIMY)
Defiance Trillion Dollar Club Index ETF (Nasdaq: TRIL)
Defiance Daily Target 2X Short LLY ETF (LLYZ)

The Board of Trustees of Tidal Trust II approved this action as part of Defiance’s ongoing review of its product lineup and its commitment to offering investors a focused suite of strategies aligned with evolving market conditions and investor demand.

The final day of trading for the funds on the Nasdaq will be Monday, January 26, 2026. After the market close on this date, the funds will be delisted and will no longer accept creation orders. Shareholders who continue to hold shares as of each fund’s liquidation date, Friday, January 30, 2026, will have their shares automatically redeemed for cash at the funds’ net asset value (NAV) calculated on the liquidation date.

Defiance encourages shareholders to consult their financial or tax advisors regarding the potential tax implications of the liquidation.

About Tidal Financial Group

Formed by ETF industry pioneers and thought leaders, Tidal Investments LLC is dedicated to revolutionizing ETF development, launch, marketing, and sales. With a focus on growing AUM, Tidal provides a comprehensive suite of services, proprietary tools, and methodologies designed to bring lasting investment ideas to market. Tidal is committed to ETF innovation, equipping issuers with the intelligence and tools needed to efficiently launch ETFs and optimize growth potential in a highly competitive space. For more information, visit www.tidalfinancialgroup.com.



For further inquiries, please contact [email protected].

Atossa Therapeutics Receives FDA Orphan Drug Designation for (Z)-Endoxifen for the Treatment of Duchenne Muscular Dystrophy

PR Newswire

Designation further supports (Z)-Endoxifen program into rare pediatric neuromuscular disease along with previously received Rare Pediatric Disease Designation

SEATTLE, Jan. 16, 2026 /PRNewswire/ — Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapies in oncology and other areas of high unmet clinical need, today announced that the U.S. Food and Drug Administration (“FDA”) Office of Orphan Products Development (“OOPD”) has granted Orphan Drug Designation to (Z)-endoxifen for the treatment of Duchenne muscular dystrophy (“DMD”).

“In addition to the previously received Rare Pediatric Disease designation, Orphan Drug Designation for (Z)-endoxifen in Duchenne muscular dystrophy is an important milestone for Atossa as we move forward developing (Z)-endoxifen for this serious and debilitating disease,” noted Steven C. Quay, M.D., Ph.D., Atossa Therapeutics President and Chief Executive Officer.

Atossa plans to continue engaging with FDA as it advances development efforts and will provide updates as appropriate.

About Orphan Drug Designation

Orphan Drug Designation is granted by FDA to therapies intended to treat rare diseases or conditions. The designation is designed to encourage drug development by offering certain potential incentives, such as regulatory support and, if the product ultimately receives marketing approval for the designated indication, eligibility for a period of market exclusivity. FDA also notes that if an “otherwise same drug” is approved first for the same indication, a sponsor may need to demonstrate that the new drug is clinically superior to the previously approved drug in order to be eligible for orphan-drug exclusivity. Orphan Drug Designation neither shortens the development time or regulatory review time of a drug nor gives the drug any advantage in the regulatory review or approval process.

About Duchenne Muscular Dystrophy

Duchenne Muscular Dystrophy is a rare, progressive, X-linked neuromuscular disorder caused by mutations in the dystrophin gene. Symptoms typically emerge in early childhood and include progressive muscle weakness, loss of ambulation, respiratory compromise, and cardiomyopathy. DMD is uniformly fatal, often in early adulthood, and despite recent therapeutic advances, there remains a substantial unmet medical need for safe, effective, and accessible treatments.

About (Z)-Endoxifen

(Z)-Endoxifen is a potent Selective Estrogen Receptor Modulator/Degrader (SERM/SERD) with demonstrated activity across multiple mechanisms of interest. Atossa is evaluating its potential applications in oncology and rare diseases. The Company’s proprietary oral formulation has shown a favorable safety profile and pharmacology distinct from tamoxifen, including ER-targeted effects and PKC inhibition. Atossa’s (Z)-Endoxifen is not approved for any indication.

Atossa’s (Z)-Endoxifen program is supported by a growing global intellectual property portfolio, including multiple recently issued U.S. patents and numerous pending applications worldwide.

About Atossa Therapeutics

Atossa Therapeutics, Inc. (Nasdaq: ATOS) is a clinical-stage biopharmaceutical company developing innovative medicines in oncology and other areas of significant unmet need. The Company’s lead product candidate, (Z)-Endoxifen, is currently in development across several clinical settings. More information is available at https://atossatherapeutics.com.

Forward-Looking Statements

This press release contains certain “forward-looking statements” within the meaning of applicable securities laws, including but not limited to, our expectations regarding the Company’s development and regulatory strategy and related milestones, the potential indications that the Company may pursue for (Z)-Endoxifen, the potential for (Z)-Endoxifen to receive regulatory approval and the timing thereof, and the potential market and growth opportunities for the Company. Words such as “expect,” “potential,” “continue,” “may,” “will,” “should,” “could,” “would,” “seek,” “intend,” “plan,” “estimate,” “anticipate,” “believe,” “design,” “predict,” “future,” or other similar expressions or statements regarding intent, belief or current expectations, are forward-looking statements.

Forward-looking statements in this press release are subject to risks and uncertainties that may cause actual results, outcomes, or the timing of actual results or outcomes to differ materially from those projected or anticipated, including, without limitation, risks and uncertainties associated with: our ability to successfully execute our strategy to shorten our clinical development timelines and pursue a metastatic breast cancer indication, DMD indication or other indications for our lead program, (Z)-Endoxifen; expected timing, completion and results of our preclinical studies, clinical trials and research and development programs; the unpredictable relationship between preclinical study results and clinical study results; the timing or likelihood of regulatory filings and approvals; the outcome or timing of necessary regulatory approvals; our ability to receive orphan-drug exclusivity for (Z)-Endoxifen for DMD; our ability to regain and maintain compliance with Nasdaq listing requirements; our ability to establish and maintain intellectual property rights covering our products; the impact of general macroeconomic conditions on our business; our ability to raise capital; and other risks and uncertainties detailed from time to time in Atossa’s filings with the SEC, including, without limitation, its Annual Reports on Form 10-K and Quarterly Reports on Form 10-Q.

Forward-looking statements are presented as of the date of this press release. Except as required by law, we do not intend to update any forward-looking statements.

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/atossa-therapeutics-receives-fda-orphan-drug-designation-for-z-endoxifen-for-the-treatment-of-duchenne-muscular-dystrophy-302663760.html

SOURCE Atossa Therapeutics Inc

Liberty All-Star® Equity Fund December 2025 Monthly Update

Liberty All-Star® Equity Fund December 2025 Monthly Update

BOSTON–(BUSINESS WIRE)–
Below is the December 2025 Monthly Update for the Liberty All-Star Equity Fund (NYSE: USA).

Liberty All-Star Equity Fund

Ticker: USA

Monthly Update, December 2025

Investment Approach:

Fund Style: Large-Cap Core

Fund Strategy: Combines three value-style and two growth-style investment managers. Those selected demonstrate a consistent investment philosophy, decision making process, continuity of key people and above-average long-term results compared to managers with similar styles.

Investment Managers:

Value Managers:

  • Aristotle Capital Management, LLC

  • Fiduciary Management, Inc.

  • Pzena Investment Management, LLC

Growth Managers:

  • Sustainable Growth Advisers, LP

  • TCW Investment Management Company

Top 20 Holdings at Month-End:

 

(38.1% of equity portfolio)

 

1

NVIDIA Corp.

5.0%

2

Microsoft Corp.

4.5%

3

Alphabet, Inc.

4.1%

4

Amazon.com, Inc.

2.6%

5

Capital One Financial Corp.

2.3%

6

Meta Platforms, Inc.

1.7%

7

Visa, Inc.

1.7%

8

Charles Schwab Corp.

1.5%

9

Wells Fargo & Co.

1.5%

10

Broadcom Inc.

1.5%

11

Fresenius Medical Care AG

1.3%

12

S&P Global, Inc.

1.3%

13

ServiceNow, Inc.

1.2%

14

Synopsys, Inc.

1.2%

15

CVS Health Corp.

1.2%

16

Parker-Hannifin Corp.

1.2%

17

Sony Group Corp.

1.1%

18

UnitedHealth Group, Inc.

1.1%

19

Booking Holdings, Inc.

1.1%

20

Baxter International, Inc.

1.0%

Holdings are subject to change.

Monthly Performance:

Performance

NAV

Market Price

Discount

Beginning of month value

$6.79

$6.13

-9.7%

End of month value

$6.84

$6.28

-8.2%

Performance for month

0.74%

2.45%

 

Performance year-to-date

8.80%

-0.11%

 

 

 

 

 

Net Assets at Month-End ($millions):

Total

$2,061.7

 

Equities

$2,022.5

 

Percent Invested

98.1%

 

Sector Breakdown* (% of equity portfolio):

Information Technology

24.9%

Financials

19.7%

Health Care

13.7%

Consumer Discretionary

10.8%

Industrials

10.4%

Communication Services

6.9%

Materials

4.9%

Consumer Staples

4.9%

Energy

2.0%

Utilities

1.3%

Real Estate

0.5%

Total Market Value

100.0%

*Based on Standard & Poor’s and MSCI Global Industry Classification Standard (GICS).

New Holdings:

IDEXX Laboratories, Inc.

McCormick & Co., Inc.

Holdings Liquidated:

Constellation Brands, Inc.

The net asset value (NAV) of a closed-end fund is the market value of the underlying investments (i.e., stocks and bonds) in the Fund’s portfolio, minus liabilities, divided by the total number of Fund shares outstanding. However, the Fund also has a market price; the value at which it trades on an exchange. If the market price is above the NAV the Fund is trading at a premium. If the market price is below the NAV the Fund is trading at a discount.

Performance returns for the Fund are total returns, which includes dividends, and are net of management fees and other Fund expenses. Returns are calculated assuming that a shareholder reinvested all distributions. Past performance cannot predict future investment results.

Performance will fluctuate with changes in market conditions. Current performance may be lower or higher than the performance data shown. Performance information shown does not reflect the deduction of taxes that shareholders would pay on Fund distributions or the sale of Fund shares. Shareholders must be willing to tolerate significant fluctuations in the value of their investment. An investment in the Fund involves risk, including loss of principal.

Sources of distributions to shareholders may include ordinary dividends, long-term capital gains and return of capital. The final determination of the source of all distributions in 2025 for tax reporting purposes will be made after year end. The actual amounts and sources of the amounts for tax reporting purposes will depend upon the Fund’s investment experience during its fiscal year and may be subject to changes based on tax regulations. Based on current estimates a portion of the distributions consist of a return of capital. These estimates may not match the final tax characterization (for the full year’s distributions) contained in shareholder 1099-DIV forms after the end of the year.

All data is as of December 31, 2025 unless otherwise noted.

Liberty All-Star® Equity Fund

1-800-241-1850

www.all-starfunds.com

[email protected]

KEYWORDS: Massachusetts United States North America

INDUSTRY KEYWORDS: Asset Management Professional Services Finance

MEDIA:

Logo
Logo

Liberty All-Star® Growth Fund, Inc. December 2025 Monthly Update

Liberty All-Star® Growth Fund, Inc. December 2025 Monthly Update

BOSTON–(BUSINESS WIRE)–
Below is the December 2025 Monthly Update for the Liberty All-Star Growth Fund, Inc. (NYSE: ASG).

Liberty All-Star Growth Fund, Inc.

Ticker: ASG

Monthly Update, December 2025

Investment Approach:

Fund Style: All-Cap Growth

Fund Strategy: Combines three growth style investment managers, each with a distinct capitalization focus (small-, mid- and large-cap) selected and continuously monitored by the Fund’s Investment Advisor.

Investment Managers:

  • Weatherbie Capital, LLC

    Small-Cap Growth

  • Congress Asset Management Company, LLP

    Mid-Cap Growth

  • Westfield Capital Management Company, L.P.

    Large-Cap Growth

Top 20 Holdings at Month-End:

 

 

(38.0% of equity portfolio)

 

 

1

 

NVIDIA Corp.

 

5.0%

2

 

Apple, Inc.

 

3.7%

3

 

Microsoft Corp.

 

3.1%

4

 

Alphabet, Inc.

 

2.8%

5

 

Amazon.com, Inc.

 

2.2%

6

 

Meta Platforms, Inc.

 

2.0%

7

 

FirstService Corp.

 

1.7%

8

 

Ollie’s Bargain Outlet Holdings, Inc.

 

1.6%

9

 

Ascendis Pharma A/S

 

1.6%

10

 

Artivion, Inc.

 

1.5%

11

 

Natera, Inc.

 

1.5%

12

 

StepStone Group, Inc.

 

1.4%

13

 

AAR Corp.

 

1.4%

14

 

Broadcom Inc.

 

1.3%

15

 

Eli Lilly & Co.

 

1.3%

16

 

EMCOR Group, Inc.

 

1.2%

17

 

Curtiss-Wright Corp.

 

1.2%

18

 

Semtech Corp.

 

1.2%

19

 

ACADIA Pharmaceuticals, Inc.

 

1.2%

20

 

Vertiv Holdings Co.

 

1.1%

Holdings are subject to change.

Monthly Performance:

Performance

NAV

Market Price

Discount

Beginning of month value

$5.99

$5.37

-10.4%

End of month value

$5.86

$5.30

-9.6%

Performance for month

-2.17%

-1.30%

 

Performance year-to-date

4.58%

2.12%

 

 

 

 

 

Net Assets at Month-End ($millions):

Total

$368.3

Equities

$367.5

Percent Invested

99.8%

Sector Breakdown* (% of equity portfolio):

Information Technology

28.6%

Industrials

22.7%

Health Care

16.8%

Consumer Discretionary

12.3%

Financials

9.8%

Communication Services

6.3%

Real Estate

2.1%

Consumer Staples

1.4%

Total Market Value

100.0%

*Based on Standard & Poor’s and MSCI Global Industry Classification Standard (GICS).

New Holdings:

Cardinal Infrastructure Group, Inc.

IDEXX Laboratories, Inc.

Ross Stores, Inc.

Salesforce, Inc.

Holdings Liquidated:

Booz Allen Hamilton Holding Corp.

CyberArk Software, Ltd.

Spotify Technology SA

SPS Commerce, Inc.

Transcat, Inc.

TransDigm Group, Inc.

The net asset value (NAV) of a closed-end fund is the market value of the underlying investments (i.e., stocks and bonds) in the Fund’s portfolio, minus liabilities, divided by the total number of Fund shares outstanding. However, the Fund also has a market price; the value at which it trades on an exchange. If the market price is above the NAV the Fund is trading at a premium. If the market price is below the NAV the Fund is trading at a discount.

Performance returns for the Fund are total returns, which includes dividends, and are net of management fees and other Fund expenses. Returns are calculated assuming that a shareholder reinvested all distributions. Past performance cannot predict future investment results.

Performance will fluctuate with changes in market conditions. Current performance may be lower or higher than the performance data shown. Performance information shown does not reflect the deduction of taxes that shareholders would pay on Fund distributions or the sale of Fund shares. Shareholders must be willing to tolerate significant fluctuations in the value of their investment. An investment in the Fund involves risk, including loss of principal.

Sources of distributions to shareholders may include ordinary dividends, long-term capital gains and return of capital. The final determination of the source of all distributions in 2025 for tax reporting purposes will be made after year end. The actual amounts and sources of the amounts for tax reporting purposes will depend upon the Fund’s investment experience during its fiscal year and may be subject to changes based on tax regulations. Based on current estimates a portion of the distributions consist of a return of capital. These estimates may not match the final tax characterization (for the full year’s distributions) contained in shareholder 1099-DIV forms after the end of the year.

All data is as of December 31, 2025 unless otherwise noted.

Liberty All-Star® Growth Fund, Inc.

1-800-241-1850

www.all-starfunds.com

[email protected]

KEYWORDS: Massachusetts United States North America

INDUSTRY KEYWORDS: Asset Management Professional Services Finance

MEDIA:

Logo
Logo

The J.M. Smucker Co. Declares Dividend

PR Newswire

ORRVILLE, Ohio, Jan. 16, 2026 /PRNewswire/ — The J.M. Smucker Co. (NYSE: SJM) today announced its Board of Directors approved a $1.10 per share dividend on the common shares of the Company. The dividend will be paid on Monday, March 2, 2026, to shareholders of record at the close of business on Friday, February 13, 2026.

About The J.M. Smucker Co. 

At The J.M. Smucker Co., it is our privilege to make food people and pets love by offering a diverse family of brands available across North America. We are proud to lead in the coffee, peanut butter, fruit spreads, frozen handheld, sweet baked goods, dog snacks, and cat food categories by offering brands consumers trust for themselves and their families each day, including Folgers®, Dunkin’®, Café Bustelo®, Jif®, Uncrustables®, Smucker’s®, Hostess®, Milk-Bone®, and Meow Mix®. Through our unwavering commitment to producing quality products, operating responsibly and ethically and delivering on our Purpose, we will continue to grow our business while making a positive impact on society. For more information, please visit jmsmucker.com.

The J.M. Smucker Co. is the owner of all trademarks referenced herein, except for Dunkin’®, which is a trademark of DD IP Holder LLC. The Dunkin’® brand is licensed to The J.M. Smucker Co. for packaged coffee products sold in retail channels, such as grocery stores, mass merchandisers, club stores, e-commerce and drug stores, and in certain away from home channels. This information does not pertain to products for sale in Dunkin’® restaurants.

 

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/the-jm-smucker-co-declares-dividend-302663742.html

SOURCE The J.M. Smucker Co.

HCI Group Declares Quarterly Cash Dividend

TAMPA, Fla., Jan. 16, 2026 (GLOBE NEWSWIRE) — The board of directors of HCI Group, Inc. (NYSE: HCI) has declared a regular quarterly cash dividend in the amount of 40 cents per common share. The dividend is scheduled to be paid March 20, 2026 to shareholders of record at the close of business February 20, 2026.

About HCI Group, Inc.

HCI Group, Inc. is a holding company with two distinct operating units. The first unit includes four top-performing insurance companies, a captive reinsurance company, and operations in claims management and real estate. The second unit, called Exzeo Group, is a leading innovator of insurance technology that utilizes advanced underwriting algorithms and data analytics. Exzeo empowers property and casualty insurers to transform underwriting outcomes and achieve industry-leading results.

HCI’s common shares trade on the New York Stock Exchange under the ticker symbol “HCI” and are included in the Russell 2000 and S&P SmallCap 600 Index. HCI Group, Inc. regularly publishes financial and other information in the Investor Information section of the company’s website. For more information about HCI Group and its subsidiaries, visit www.hcigroup.com. Exzeo’s common shares trade on the New York Stock Exchange under the ticker symbol “XZO.” For more information about Exzeo, visit www.exzeo.com.

Forward-Looking Statements

This news release may contain forward-looking statements made pursuant to the Private Securities Litigation Reform Act of 1995. Words such as “anticipate,” “estimate,” “expect,” “intend,” “plan,” “confident,” “prospects” and “project” and other similar words and expressions are intended to signify forward-looking statements. Forward-looking statements are not guarantees of future results and conditions but rather are subject to various risks and uncertainties. There can be no assurance, for example, that changes in the company’s cash flow and cash balances will not impact the ability or willingness of HCI Group to pay a dividend. Some of these risks and uncertainties are identified in the company’s filings with the Securities and Exchange Commission. Should any risks or uncertainties develop into actual events, these developments could have material adverse effects on the company’s business, financial condition and results of operations. HCI Group, Inc. disclaims all obligations to update any forward-looking statements.

Company Contact:

Nat Otis
Investor Relations
HCI Group, Inc.
Tel (813) 405-5341
[email protected]

Investor Relations Contact:

Matt Glover
Gateway Group, Inc.
Tel (949) 574-3860
[email protected]



NusaTrip Incorporated Announces Waiver of Society Pass Lock-Up Agreement

Jakarta, Jan. 16, 2026 (GLOBE NEWSWIRE) — NusaTrip Incorporated (Nasdaq: NUTR) (“NusaTrip,” “NUTR,” or the “Company”), a travel ecosystem with geographical specialization in Southeast Asia and Asia-Pacific, today announced that its initial public offering underwriter, Cathay Securities, Inc., has given its consent to grant an early release to Society Pass Incorporated (Nasdaq: SOPA) from its securities lock-up agreement associated with NusaTrip’s initial public offering.  

NusaTrip consummated its initial public offering in August 2025, and pursuant to the underwriting agreement between NusaTrip Incorporated and Cathay Securities, Inc., Society Pass Incorporated agreed, subject to certain exceptions, not to offer, pledge, sell, contract to sell, grant, lend or otherwise transfer or dispose of, directly or indirectly, any NusaTrip securities for a period of six months from the date of commencement of sale of NusaTrip’s initial public offering. Cathay Securities has given its consent to grant an early release to Society Pass from this lock-up period, as of January 15th, 2026.

About NusaTrip Incorporated

Established in 2015 and headquartered in Jakarta, Indonesia, NusaTrip Incorporated is a travel ecosystem with geographical specialization in Southeast Asia (SEA) and Asia-Pacific (APAC). NusaTrip is an acquisitions-focused company. Mergers and acquisitions of offline travel agencies play a pivotal role in our growth strategy. We have demonstrated an ability to execute accretive and synergistic acquisitions as well as integrate and fundamentally improve our acquired businesses. We have completed acquisitions of VLeisure and VIT, both travel companies in Vietnam. We will continue to focus on the acquisition of other synergistic companies, and we are currently looking to acquire travel agencies operating in PRC, Hong Kong, Philippines, Thailand, Singapore, Malaysia, India, and UAE. We aim to bring travelers from the rest of the world to SEA and APAC (inbound travel) and bring travelers from SEA and APAC to the rest world (outbound travel).

We are the first Indonesian-based online travel agent (OTA) in Indonesia to receive International Air Transport Association (IATA) accreditation. IATA gives OTA’s access to all airline fares and inventories. For being the first IATA-accredited OTA in Indonesia, we have first-hand fares from both full-service and low-cost carriers.

Please visit the Company’s website at: https://www.nusatrip.com/.

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. You can identify forward-looking statements by the fact that they do not relate strictly to historical or current facts. These statements may include words such as “anticipate”, “estimate”, “expect”, “project”, “plan”, “intend”, “believe”, “may”, “will”, “should”, “can have”, “likely” and other words and terms of similar meaning. Forward-looking statements represent NusaTrip Incorporated’s current expectations regarding future events and are subject to known and unknown risks and uncertainties that could cause actual results to differ materially from those implied by the forward-looking statements. Among those risks and uncertainties are market conditions, including the trading price and volatility of NusaTrip Incorporated’s common stock and risks relating to NusaTrip Incorporated’s business and the satisfaction of closing conditions in the underwriting agreement related to the offering.

Contact Information:

NusaTrip Incorporated

Anson Neo
Chief Executive Officer
[email protected]

Skyline Corporate Communications Group, LLC

Scott Powell, President
1177 Avenue of the Americas, 5th Floor
New York, New York 10036
Office: (646) 893-5835 x2
Email: [email protected]



J & J SNACK FOODS SCHEDULES FISCAL 2026 FIRST QUARTER EARNINGS CONFERENCE CALL AND WEBCAST

MOUNT LAUREL, N.J., Jan. 16, 2026 (GLOBE NEWSWIRE) —  J & J Snack Foods Corp. (Nasdaq: JJSF) today announced that it will release financial results for its fiscal first quarter ended December 27, 2025, before the stock market opens on Tuesday, February 3, 2026. The Company will hold a conference call and webcast to discuss the results at 10:00 a.m. Eastern Time that same day.

Investors interested in participating in the live call can pre-register by clicking on this Registration Link to receive the dial-in number and a personal PIN, which are required to access the conference call.  The live audio webcast will be accessible on the Company’s investor relations website at https://www.jjsnack.com/investors/ or directly at here.  

About J & J Snack Foods Corp.

J & J Snack Foods Corp. (Nasdaq: JJSF) is a leader and innovator in the snack food and frozen beverage industry. For over fifty years, the company has specialized in delicious snack and beverage brands for the foodservice and retail segments, serving up fun across the U.S. market. J & J Snack Foods’ core brands include SUPERPRETZEL, the #1 soft pretzel brand, ICEE and SLUSH PUPPIE frozen beverages, and Dippin’ Dots, the original beaded ice cream. The company’s broad brand portfolio also includes LUIGI’S Real Italian Ice, MINUTE MAID* frozen ices, WHOLE FRUIT frozen fruit bars, DOGSTERS ice cream style treats for dogs, ¡Hola! Churros, THE FUNNEL CAKE FACTORY funnel cakes and fries, and bakery brands including MARY B’S, DADDY RAY’S, COUNTRY HOME BAKERS, and HILL & VALLEY. For more information, please visit http://www.jjsnack.com. *MINUTE MAID is a registered trademark of The Coca-Cola Company.

Investor Contact:

Reed Anderson, ICR
(646) 277-1260
[email protected]